Predictors of mortality of Acinetobacter baumannii infections: A 2-year prospective study in a Greek surgical intensive care unit

Am J Infect Control. 2010 Oct;38(8):631-5. doi: 10.1016/j.ajic.2010.01.009. Epub 2010 May 14.

Abstract

Background: Nosocomial infections are a frequent and continuously increasing problem worldwide, have a rapidly increasing multidrug resistance to antibiotics, and are associated with significant morbidity and mortality.

Objective: Our objectives were to evaluate Acinetobacter baumannii infection incidence in our surgical intensive care unit (SICU), the clinical features and outcome of these patients, and, particularly, to investigate predictors of A baumannii infection-related mortality.

Methods: Ours was a prospective study of all patients with ICU-acquired A baumannii infection from January 1, 2006, to December 31, 2007.

Results: Among 680 patients, 60 (8.8%) sustained A baumannii infection. Mean age was 68.4 ± 6.2 years, Acute Physiology and Chronic Health Evaluation (APACHE) II score on SICU admission 20.6 ± 8.1 and Sequential Organ Failure Assessment (SOFA) score on infection day 9.5 ± 4.2 (women: 50%). Multidrug resistance, morbidity, and mortality were 45%, 65%, and 46.6% (n = 28), respectively. In multivariate analysis, age (P = .03; odds ratio [OR], 1.13; 95% confidence interval [CI]: 1.018-1.259), acute renal failure (P = .001; OR, 17.9; 95% CI: 6.628-75.565), and thrombocytopenia (P = .03; OR, 26.4; 95% CI: 1.234-56.926) complicating the infection and subsequent Enterococcus faecium bacteremia (P = .01; OR, 3.5; 95% CI: 1.84-6.95) were mortality predictors.

Conclusion: A baumannii infections are frequent and associated with high drug multiresistance, morbidity, and mortality. Age, renal failure, thrombocytopenia, and subsequent E faecium bacteremia were predictors of A baumannii infection-associated mortality.

MeSH terms

  • Acinetobacter Infections / epidemiology
  • Acinetobacter Infections / mortality*
  • Acinetobacter baumannii*
  • Aged
  • Aging
  • Anti-Bacterial Agents / therapeutic use
  • Bacteremia / epidemiology
  • Cross Infection / epidemiology
  • Cross Infection / mortality*
  • Drug Resistance, Multiple, Bacterial
  • Enterococcus faecium
  • Gram-Positive Bacterial Infections / epidemiology
  • Greece / epidemiology
  • Humans
  • Intensive Care Units / statistics & numerical data*
  • Prospective Studies
  • Risk Factors
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents